Citius Oncology

Citius Oncology EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Citius Oncology (CTOR) as of Nov 22, 2026 is -11.08. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 512.71 — a change of -102.16% (lower).

EV/FCF

-11.08

YoY

-102.16%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Citius Oncology is 2025 -11.08 . EV/FCF (Enterprise Value to Free Cash Flow) of Citius Oncology was 2024 512.71 . It decreases by -102.16% lower compared to the previous year.

The Citius Oncology EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2022
-1,271.27 USD
Jan 1, 2023
-101.41 USD
Jan 1, 2024
512.71 USD
Jan 1, 2025
-11.08 USD
The Citius Oncology EV/FCF history
YEAREV/FCFYoY
-11.08-102.16%
512.71-605.57%
-101.41-92.02%
-1,271.27—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Citius Oncology Stock analysis

What does Citius Oncology do? Citius Oncology, Inc. develops and commercializes targeted oncology therapies, with its lead product candidate LYMPHIR for treating persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein that targets IL-2 receptors on cancer cells, inhibiting protein synthesis and causing cell death. The company focuses on relapsed or refractory cutaneous T-cell lymphoma (CTCL) patients after at least one prior systemic therapy, with the product indicated for Stage I-III disease. Citius Oncology, Inc. is a pharmaceutical company engaged in developing and commercializing targeted oncology therapies, with LYMPHIR as its primary product. The company's lead candidate targets CTCL, a rare non-Hodgkin lymphoma, and is designed for patients who have failed prior systemic treatments. The therapeutic mechanism involves binding to IL-2 receptors, delivering diphtheria toxin fragments to inhibit protein synthesis within cancer cells. The company's commercial strategy centers on LYMPHIR, which is positioned for relapsed or refractory CTCL patients requiring additional treatment options. LYMPHIR's mechanism of action specifically targets IL-2 receptors on cancer cells, leading to cell death through inhibition of protein synthesis. This targeted approach differentiates the product in the oncology therapy market for rare lymphoma subtypes. Citius Oncology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Citius Oncology stock

EV/FCF (Enterprise Value to Free Cash Flow) of Citius Oncology is -11.08 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Citius Oncology changed from 512.71 to -11.08, representing a -102.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Citius Oncology since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Citius Oncology with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Citius Oncology

All Key Metrics — Citius Oncology